<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316807</url>
  </required_header>
  <id_info>
    <org_study_id>2012ZX10002001003004004</org_study_id>
    <nct_id>NCT03316807</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults</brief_title>
  <acronym>HIV</acronym>
  <official_title>Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suping Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanxi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uptake, adherence, and completion of vaccination among HIV-infected adults were low, and&#xD;
      their immune function and immune response to hepatitis B vaccination were also suboptimal,&#xD;
      indicating that the current practice of hepatitis B vaccination can't protect HIV-infected&#xD;
      adults from HBV infection. And the persistence of immunity induced by hepatitis B vaccination&#xD;
      remains a challenge.&#xD;
&#xD;
      This is a randomized, open-label trial, conducted among HIV-infected adults with drug&#xD;
      rehabilitation. This study will compare the immunogenicity, immune persistence, and safety of&#xD;
      three intramuscular 20µg and 60µg recombinant hepatitis B vaccines at months 0, 1, and 6&#xD;
      among HIV-infected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized in a ratio of 1:1 into 20 µg recombinant hepatitis B vaccine&#xD;
      group or 60µg recombinant hepatitis B vaccine group. The 20 µg group will receive three&#xD;
      intramuscular injections of the 20 µg recombinant hepatitis B vaccine, while the 60 µg group&#xD;
      will receive three intramuscular injections of the 60 µg dose at months 0, 1 and 6,&#xD;
      respectively. HBsAg and anti-HBs will be tested during the study period. Adverse reactions&#xD;
      will be recorded after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Rate of Participants With Anti-HBs Seroconversion at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Concentration at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Rate of Participants With Anti-HBs Seroconversion at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events After Vaccination</measure>
    <time_frame>Within 7 days after the vaccination</time_frame>
    <description>Occurrence of adverse reactions within 7 days after vaccination with the hepatitis B vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events After Vaccination</measure>
    <time_frame>Within 28 days after vaccination</time_frame>
    <description>Occurrence of adverse reactions within 28 days after vaccination with the hepatitis B vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE) Occurred During 42 Month</measure>
    <time_frame>Month 0-42</time_frame>
    <description>Occurrence of Serious adverse events (SAE) within 42 month after vaccination with the hepatitis B</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number and Rate of Participants With Anti-HBs High-level Response at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and Rate of Participants With Anti-HBs High-level Response at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-HBs Concentration at Month 6 Before the Third Injection</measure>
    <time_frame>Month 6 before the third injection</time_frame>
    <description>Anti-HBs concentration at month 6 before the third injection as measured by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and Rate of Participants With Anti-HBs Seroconversion at Month 6 Before the Third Injection</measure>
    <time_frame>Month 6 before the third injection</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and Rate of Participants With Anti-HBs High-level Response at Month 6 Before the Third Injection</measure>
    <time_frame>Month 6 before the third injection</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and Rate of Participants With Anti-HBs Seroconversion at Month 42</measure>
    <time_frame>Month 42</time_frame>
    <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Hepatitis B Vaccine</condition>
  <arm_group>
    <arm_group_label>60 µg dose hepatitis B vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 µg dose hepatitis B vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>60 µg dose hepatitis B vaccine</intervention_name>
    <description>three-dose, 60 µg per dose</description>
    <arm_group_label>60 µg dose hepatitis B vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20 µg dose hepatitis B vaccine</intervention_name>
    <description>three-dose, 20 µg per dose</description>
    <arm_group_label>20 µg dose hepatitis B vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected&#xD;
&#xD;
          -  Aged between 18 and 70 years&#xD;
&#xD;
          -  Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface&#xD;
             antibody (anti-HBs) at enrollment&#xD;
&#xD;
          -  Willing to adhere to the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being pregnant&#xD;
&#xD;
          -  Acute cytolysis in the last three months before enrollment&#xD;
&#xD;
          -  Any vaccination before or during the month preceding enrollment&#xD;
&#xD;
          -  Any Intolerance or allergy to any component of the vaccine&#xD;
&#xD;
          -  Ongoing opportunistic infection&#xD;
&#xD;
          -  Hematological disorder&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Unexplained fever the week before enrollment&#xD;
&#xD;
          -  Immunosuppressive or immunomodulating treatment in the last six months&#xD;
&#xD;
          -  Liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suping Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanxi Medical University</affiliation>
  </overall_official>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <results_first_submitted>December 20, 2020</results_first_submitted>
  <results_first_submitted_qc>December 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Suping Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B, Vaccine</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>HIV</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>60 µg Dose Hepatitis B Vaccine</title>
          <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
        </group>
        <group group_id="P2">
          <title>20 µg Dose Hepatitis B Vaccine</title>
          <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>60 µg Dose Hepatitis B Vaccine</title>
          <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
        </group>
        <group group_id="B2">
          <title>20 µg Dose Hepatitis B Vaccine</title>
          <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="11.4"/>
                    <measurement group_id="B2" value="38.2" spread="10.6"/>
                    <measurement group_id="B3" value="39.3" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Han ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zhuang ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 7</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
        <time_frame>Month 7</time_frame>
        <population>83 and 82 patients in the IM60（60μg recombinant hepatitis B vaccine） and IM20（20μg recombinant hepatitis B vaccine） groups completed the followed-up at months 7.</population>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 7</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
          <population>83 and 82 patients in the IM60（60μg recombinant hepatitis B vaccine） and IM20（20μg recombinant hepatitis B vaccine） groups completed the followed-up at months 7.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HBs Concentration at Month 7</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ).</description>
        <time_frame>Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Concentration at Month 7</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ).</description>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623.3" lower_limit="427.7" upper_limit="836.9"/>
                    <measurement group_id="O2" value="469.4" lower_limit="326.8" upper_limit="611.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HBs Concentration at Month 12</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Concentration at Month 12</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
          <units>mIU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.4" lower_limit="132.6" upper_limit="448.1"/>
                    <measurement group_id="O2" value="264.4" lower_limit="95.3" upper_limit="433.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 12</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 12</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA（Chemiluminescent Microparticle Immunoassay）.The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events After Vaccination</title>
        <description>Occurrence of adverse reactions within 7 days after vaccination with the hepatitis B vaccine</description>
        <time_frame>Within 7 days after the vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events After Vaccination</title>
          <description>Occurrence of adverse reactions within 7 days after vaccination with the hepatitis B vaccine</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events After Vaccination</title>
        <description>Occurrence of adverse reactions within 28 days after vaccination with the hepatitis B vaccine</description>
        <time_frame>Within 28 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events After Vaccination</title>
          <description>Occurrence of adverse reactions within 28 days after vaccination with the hepatitis B vaccine</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAE) Occurred During 42 Month</title>
        <description>Occurrence of Serious adverse events (SAE) within 42 month after vaccination with the hepatitis B</description>
        <time_frame>Month 0-42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAE) Occurred During 42 Month</title>
          <description>Occurrence of Serious adverse events (SAE) within 42 month after vaccination with the hepatitis B</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 7</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
        <time_frame>Month 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 7</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 12</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 12</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anti-HBs Concentration at Month 6 Before the Third Injection</title>
        <description>Anti-HBs concentration at month 6 before the third injection as measured by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
        <time_frame>Month 6 before the third injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Concentration at Month 6 Before the Third Injection</title>
          <description>Anti-HBs concentration at month 6 before the third injection as measured by CMIA（Chemiluminescent Microparticle Immunoassay）.</description>
          <units>mIU/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.9" lower_limit="78.1" upper_limit="219.7"/>
                    <measurement group_id="O2" value="130.6" lower_limit="72.5" upper_limit="188.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 6 Before the Third Injection</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
        <time_frame>Month 6 before the third injection</time_frame>
        <population>83 and 70 patients in the IM60 and IM20 groups completed the followed-up at month 6 before the third injection.</population>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 6 Before the Third Injection</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
          <population>83 and 70 patients in the IM60 and IM20 groups completed the followed-up at month 6 before the third injection.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 6 Before the Third Injection</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
        <time_frame>Month 6 before the third injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs High-level Response at Month 6 Before the Third Injection</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA. and anti-HBs concentrations ≥100 mIU/ml were high-level response.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 42</title>
        <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>60 µg Dose Hepatitis B Vaccine</title>
            <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
          </group>
          <group group_id="O2">
            <title>20 µg Dose Hepatitis B Vaccine</title>
            <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Rate of Participants With Anti-HBs Seroconversion at Month 42</title>
          <description>The measurements of anti-HBs antibodies were determined quantitatively by CMIA(Chemiluminescent Microparticle Immunoassay ). The accepted protective serum anti-HBs level was ≥10 mIU/ml.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>60 µg Dose Hepatitis B Vaccine</title>
          <description>60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
60 µg dose hepatitis B vaccine: three-dose, 60 µg per dose</description>
        </group>
        <group group_id="E2">
          <title>20 µg Dose Hepatitis B Vaccine</title>
          <description>20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6&#xD;
20 µg dose hepatitis B vaccine: three-dose, 20 µg per dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>induration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suping Wang, PhD</name_or_title>
      <organization>Shanxi Medical University</organization>
      <phone>#86-351-4135103</phone>
      <email>spwang88@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

